CALCA and osteoporosis: The rate of treatment was lowest in the Kern CCT (31% of those with a treatment indication) [68]; among the remaining trials, more than two-thirds (69 to 80%) of those with a treatment indication reported using some form of anti-osteoporosis drugs during follow-up (variable treatments across studies, and sometimes including those such as calcitonin and hormone replacement therapy, which are no longer recommended; see Table 3).